Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR-400 vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
FDA-approved: Symptomatic management of chronic obstructive pulmonary disease (COPD) and other bronchospastic disorders.,Off-label: Treatment of bronchial asthma, pulmonary hypertension, and as an adjunct in heart failure.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Hepatic metabolism via CYP1A2, CYP3A4, and CYP2E1; undergoes N-demethylation and oxidation to inactive metabolites.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal (70% unchanged), hepatic metabolism (30%)
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40% bound, primarily to albumin
55–65% bound to plasma proteins, primarily albumin.
0.5 L/kg (approximates total body water; indicates distribution into extracellular fluid)
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 95-100% (well absorbed from gastrointestinal tract)
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 10-50 m L/min: 400 mg every 8-12 hours; GFR <10 m L/min: 400 mg every 12-24 hours.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 400 mg every 8-12 hours; Child-Pugh Class C: 400 mg every 12-24 hours.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
6 months to 2 years: 8-12 mg/kg/day divided every 6 hours; 2-12 years: 12-16 mg/kg/day divided every 6 hours; maximum 600 mg/day.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower end of dosing range (400 mg every 8 hours) and titrate based on renal function and tolerability.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
None.
No FDA black box warning exists for this drug.
Cardiovascular: May cause hypotension, tachycardia, or arrhythmias; use with caution in patients with cardiovascular disease.,CNS: May cause insomnia, anxiety, or seizures; adjust dose in elderly or with hepatic impairment.,Renal: Excreted largely unchanged; caution in renal impairment.,Drug interactions: Increased toxicity with cimetidine, ciprofloxacin, and others that inhibit CYP1A2.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to dyphylline or any xanthine derivative.,Acute myocardial infarction.,Hypotension.,Uncontrolled arrhythmias.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid high-caffeine foods (coffee, tea, cola, chocolate) as they increase risk of side effects. Charcoal-broiled foods may decrease drug absorption. High-fat meals may delay absorption; take on an empty stomach for consistent effect.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for transient neonatal hypoglycemia, tachycardia, and irritability due to maternal xanthine exposure. Avoid use unless benefit outweighs risk.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Diphylline (active ingredient) is excreted into breast milk. M/P ratio not established. Potential for irritability and sleep disturbance in infants. Caution advised; consider alternative therapies.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No well-established pharmacokinetic studies in pregnancy. However, plasma clearance of xanthines may decrease in late pregnancy due to reduced hepatic metabolism. Consider monitoring drug levels and adjusting dose to maintain therapeutic range. Initiate at lower end of dosing, titrate based on response and toxicity.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
DILOR-400 (diprophylline) is a xanthine bronchodilator with similar efficacy to theophylline but with reduced central nervous system stimulation. Monitor serum levels for therapeutic range (10-20 mcg/m L). Caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders. Adjust dose in hepatic impairment and elderly. Avoid concurrent use with other xanthines.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not exceed recommended dose.,Do not crush or chew extended-release tablets.,Report nausea, vomiting, palpitations, or seizures immediately.,Avoid caffeine-containing foods and beverages.,Do not smoke or stop smoking without consulting doctor as dose may need adjustment.,Keep a regular dosing schedule; do not double up missed doses.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR-400 vs AEROLATE SR, answered by our medical review team.
DILOR-400 is a Bronchodilator that works by Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR-400 and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR-400 is: 400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR-400 and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR-400 is classified as Category C. Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for trans. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.